(Q42996587)

12 November 2017

title

Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C. (English)

1 reference

12 November 2017

1 reference

A Hyman

1

1 reference

12 November 2017

C Yim

2

1 reference

12 November 2017

M Krajden

3

1 reference

12 November 2017

S Read

4

1 reference

12 November 2017

A S Basinski

5

1 reference

12 November 2017

I Wanless

6

1 reference

12 November 2017

G Levy

7

1 reference

12 November 2017

J Heathcote

8

1 reference

12 November 2017

publication date

1 July 1999

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

6

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

329-336

1 reference

Effect of Vidarabine on Chronic Hepatitis B Virus Infection

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00161.X

Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00161.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00161.X

Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00161.X

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00161.X

Interferon-associated lymphocyte 2',5'-oligoadenylate synthetase in acute and chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00161.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00161.X

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00161.X

16, 16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00161.X

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00161.X

10.1046/J.1365-2893.1999.00161.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference